Home » Actelion Wins FDA Approval for Lung Disorder Therapy
Actelion Wins FDA Approval for Lung Disorder Therapy
October 22, 2013
Actelion won U.S. approval for the lung drug Opsumit, giving the Swiss company a successor to a best-selling medicine that loses patent protection in late 2015. The FDA said it approved Opsumit, also known as macitentan, as a once-daily pill for the treatment of pulmonary arterial hypertension.